Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Ferring Pharmaceuticals
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS), in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer
To demonstrate that LUTS relief with degarelix is non-inferior to goserelin plus bicalutamide, based on a reduction in IPSS at 12 weeks as compared to baseline.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
Ensayo clínico para evaluar la efectividad de degarelix en ciclos de reproducción asistida
? To evaluate the synchrony of the follicle cohort at the start of stimulation associated with a mid-luteal injection of degarelix compared to placebo ? To describe the endometrial receptivity associ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
A study investigating a new treatment for patients with early septic shock
Show that the onset of action allows for FE 202158 to be used as primary vasopressor treatment in patients with vasodilatory hypotension in early septic shock.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
The PEACE Study: Investigating the Pharmacodynamics and Pharmacokinetics of FE 106483 Tablets in a Single Dose Study in Children with Nocturnal Enuresis. A Randomised, Double-Blind and Placebo-Controlled Study
To investigate the pharmacodynamic profile of 3 different dose levels of FE 106483 tablets in children with nocturnal enuresis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme
Entre 18 ans
et 99 ans
Ferring Pharmaceuticals
MAJ Il y a 4 ans
FERRING FE200486 CS29 : Essai de phase 3 évaluant l’efficacité d’une administration mensuelle de dégarelix, chez des patients ayant un cancer de la prostate hormono-sensible. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-label, multi-centre, uncontrolled, trial investigating degarelix one-month dosing regimen administered as intermittent androgen deprivation (IAD) for one cycle in patients with prostate cancer...
Pays
France
Organes
Prostate
Spécialités
Hormonothérapie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals Ltd
MAJ Il y a 4 ans
A prospective, randomised study comparing a 3-sachet Picolax® treatment with the standard 2-sachet Picolax® for bowel cleansing prior to colonoscopy
The primary objective of this study is to demonstrate the superiority of a 3-sachet Picolax® treatment regimen over the standard 2-sachet Picolax®. Overall quality of the bowel preparation will be de...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
A randomised, double-blind, parallel groups, placebo-controlled, multi-centre study assessing the effects of a selective oxytocin antagonist (barusiban) and a mixed oxytocin antagonist – vasopressin V1a antagonist (atosiban) administered intravenously on luteal phase uterine contractions in oocyte donors supplemented with vaginal progesterone
To evaluate the effects of barusiban and atosiban compared to placebo on luteal phase uterine contractions in oocyte donors supplemented with progesterone
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
IPSS [ Time Frame: Three months after dosing ] [ Designated as safety issue: No ]
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy
•To demonstrate that degarelix is effective with respect to achieving and maintaining testosterone suppression to castrate levels, evaluated as the proportion of patients with testosterone suppression...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 4 ans
A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoing an assisted reproductive technology programme
To investigate the dose-response relationship of FE 999049 with respect to ovarian response in patients undergoing controlled ovarian stimulation
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4